InflaRx is a Nasdq-listed inno­v­a­tive biotech­nol­ogy com­pany. InflaRx devel­ops first-in-class drugs against acute and chronic inflam­ma­tory dis­eases. The main focus is on the devel­op­ment of mon­o­clonal anti­bod­ies that inter­fere with the com­ple­ment sys­tem to com­bat life-threat­en­ing inflam­ma­tory dis­eases — such as COVID-19.